Clinical Trial Update: TAS-OX for Refractory Metastatic Colon Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TAS-OX in refractory metastatic colon cancer (colorectal neoplasms) across Phase 1 and Phase 2; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Neoplasms

Drugs mentioned

• TAS-OX (TAS-OX)

Snippet

Sponsor: Yale University | Conditions: Colorectal Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-20